Cargando…
Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
(131)I-MIBG therapy for neuroendocrine tumours may be dose limited. The common range of applied cumulative activities is 10-40 GBq. We report the uneventful cumulative administration of 111 GBq (= 3 Ci) (131)I-MIBG in a patient with metastatic paraganglioma. Ten courses of (131)I-MIBG therapy were g...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277473/ https://www.ncbi.nlm.nih.gov/pubmed/22277577 http://dx.doi.org/10.1186/1748-717X-7-8 |
_version_ | 1782223495752581120 |
---|---|
author | Ezziddin, Samer Sabet, Amir Ko, Yon-Dschun Xun, Sunny Matthies, Alexander Biersack, Hans-Jürgen |
author_facet | Ezziddin, Samer Sabet, Amir Ko, Yon-Dschun Xun, Sunny Matthies, Alexander Biersack, Hans-Jürgen |
author_sort | Ezziddin, Samer |
collection | PubMed |
description | (131)I-MIBG therapy for neuroendocrine tumours may be dose limited. The common range of applied cumulative activities is 10-40 GBq. We report the uneventful cumulative administration of 111 GBq (= 3 Ci) (131)I-MIBG in a patient with metastatic paraganglioma. Ten courses of (131)I-MIBG therapy were given within six years, accomplishing symptomatic, hormonal and tumour responses with no serious adverse effects. Chemotherapy with cisplatin/vinblastine/dacarbazine was the final treatment modality with temporary control of disease, but eventually the patient died of progression. The observed cumulative activity of (131)I-MIBG represents the highest value reported to our knowledge, and even though 12.6 GBq of (90)Y-DOTATOC were added intermediately, no associated relevant bone marrow, hepatic or other toxicity were observed. In an individual attempt to palliate metastatic disease high cumulative activity alone should not preclude the patient from repeat treatment. |
format | Online Article Text |
id | pubmed-3277473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32774732012-02-11 Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG Ezziddin, Samer Sabet, Amir Ko, Yon-Dschun Xun, Sunny Matthies, Alexander Biersack, Hans-Jürgen Radiat Oncol Case Report (131)I-MIBG therapy for neuroendocrine tumours may be dose limited. The common range of applied cumulative activities is 10-40 GBq. We report the uneventful cumulative administration of 111 GBq (= 3 Ci) (131)I-MIBG in a patient with metastatic paraganglioma. Ten courses of (131)I-MIBG therapy were given within six years, accomplishing symptomatic, hormonal and tumour responses with no serious adverse effects. Chemotherapy with cisplatin/vinblastine/dacarbazine was the final treatment modality with temporary control of disease, but eventually the patient died of progression. The observed cumulative activity of (131)I-MIBG represents the highest value reported to our knowledge, and even though 12.6 GBq of (90)Y-DOTATOC were added intermediately, no associated relevant bone marrow, hepatic or other toxicity were observed. In an individual attempt to palliate metastatic disease high cumulative activity alone should not preclude the patient from repeat treatment. BioMed Central 2012-01-25 /pmc/articles/PMC3277473/ /pubmed/22277577 http://dx.doi.org/10.1186/1748-717X-7-8 Text en Copyright ©2012 Ezziddin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Ezziddin, Samer Sabet, Amir Ko, Yon-Dschun Xun, Sunny Matthies, Alexander Biersack, Hans-Jürgen Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG |
title | Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG |
title_full | Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG |
title_fullStr | Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG |
title_full_unstemmed | Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG |
title_short | Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG |
title_sort | repeated radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)i-mibg |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277473/ https://www.ncbi.nlm.nih.gov/pubmed/22277577 http://dx.doi.org/10.1186/1748-717X-7-8 |
work_keys_str_mv | AT ezziddinsamer repeatedradionuclidetherapyinmetastaticparagangliomaleadingtothehighestreportedcumulativeactivityof131imibg AT sabetamir repeatedradionuclidetherapyinmetastaticparagangliomaleadingtothehighestreportedcumulativeactivityof131imibg AT koyondschun repeatedradionuclidetherapyinmetastaticparagangliomaleadingtothehighestreportedcumulativeactivityof131imibg AT xunsunny repeatedradionuclidetherapyinmetastaticparagangliomaleadingtothehighestreportedcumulativeactivityof131imibg AT matthiesalexander repeatedradionuclidetherapyinmetastaticparagangliomaleadingtothehighestreportedcumulativeactivityof131imibg AT biersackhansjurgen repeatedradionuclidetherapyinmetastaticparagangliomaleadingtothehighestreportedcumulativeactivityof131imibg |